December 7, 2020 Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas
November 5, 2020 Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies
June 26, 2020 Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
